CRC (N = 65), a Kaplan-Meier analysis and the log-rank test revealed that systemic chemotherapy (P = 0.023) and the modified Glasgow Prognostic Score (mGPS) (P = 0.00001) were associated with the 3-month mortality rate. Multivariate analyses using these two factors revealed that the mGPS (0/1, 2) (odds ratio 8.087; 95 % CI 1.512-43.25; P = 0.015) was an independent risk factor for the 3-month mortality rate. Conclusion The mGPS is an important independent predictor of the 3-month mortality rate in patients who undergo surgical intervention with systemic chemotherapy for synchronous PC from CRC. The mGPS could aid surgeons in choosing the appropriate treatment strategy and best care for patients.
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Introduction
Synchronous peritoneal carcinomatosis (PC) from colorectal cancer (CRC) is detected in 4.8-7 % of patients at the time of the first diagnosis of a primary colorectal tumor [1, 2] . PC from CRC is considered to be a terminal condition [median survival time (MST): 5.2-12.6 months] [2] [3] [4] . Recently, multi-modality therapy approaches, using systemic chemotherapy plus complete cytoreductive surgery (CCRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) have been shown to significantly increase the overall survival. A randomized trial demonstrated a statistically significant survival advantage for this therapeutic approach compared to systemic chemotherapy alone [5] . Another study reported that those treated with CCRS plus HIPEC demonstrated an extended MST of 48-63 months and a 5-year survival rate of 51 % [6] . However, the patient population in that study was limited to patients younger than 66 years old, with asymptomatic PC from CRC with no extra-abdominal malignancy, who had a good general status and no disease progression after 2-3 months of neoadjuvant chemotherapy. In addition, the treatment regimen caused a high rate of complications (23-53 %) [5, [7] [8] [9] . These findings indicate the possibility that there may be no benefit of this treatment for patients who die within 3 months of intervention.
In particular, the 5-year survival rate of synchronous PC from CRC (8.1 %) was worse than that of metachronous PC from CRC (25.4 %) [10] . The presence and extent of PC from CRC is frequently diagnosed during surgery, with 91 % of cases of PC from CRC not preoperatively detected [11] . This presents an issue to the operating surgeon in choosing the appropriate treatment strategy, which can include CCRS plus intraperitoneal chemotherapy (IP) and systemic chemotherapy; temporary surgery, such as a stoma; systemic chemotherapy alone or best supportive care (BSC).
The specific aim of this study was to investigate the risk factors associated with the 3-month mortality rate in patients with synchronous PC from CRC, who underwent surgical intervention, to identify risk factors to predict early mortality in patients with synchronous PC from CRC.
Methods

Registry data collection
All patients referred for surgical intervention without intraperitoneal chemotherapy for synchronous PC from CRC at Hiroshima University between September 1992 and December 2012 were included in the study. These patients were selected perioperatively according to the following criteria: surgically and histologically proven synchronous PC from CRC, with an Eastern Cooperative Oncology Group (ECOG) performance status >2. Patients with metachronous PC from CRC, appendiceal carcinoma or peritoneal pseudomyxoma were excluded.
Routine laboratory measurements, including the levels of serum C-reactive protein (CRP), albumin and tumor markers, such as carcinoembryonic antigen (CEA) and carbohydrate antigen , were sampled within a month prior to surgical intervention in all patients. Ethical approval for the study was granted by the Local Board of Ethics and all the study participants provided written informed consent prior to the commencement of the study.
Surgical intervention
All patients were considered to have undergone either CCRS or non-CCRS, based on the results of preoperative abdominal computed tomography (CT), magnetic resonance imaging (MRI) and/or positron emission tomography (PET)-CT. The suitability of a curative or non-curative operation for each patient was based on the consensus reached at multidisciplinary meetings.
The presence of peritoneal metastasis was diagnosed at the time of the operation and was confirmed by a pathological analysis. All patients included in this study received a final diagnosis of PC from CRC at the time of the operation for colorectal cancer and underwent surgical intervention.
CCRS was performed in all cases with a preoperative diagnosis when it was possible to perform a curative operation to remove all visible intraperitoneal tumor deposits (R0 resection), the primary colorectal tumor (which included D2 systemic mesenteric lymph node dissection) and other metastases (which included hepatic, ovarian or uterine metastases), except in cases with gross peritoneal or lung metastases. Patients with <4 lesions and liver metastases measuring <5 cm underwent resection of the liver metastases.
Non-CCRS was performed in cases that were ineligible for curative surgery, which was defined as unresectable extraperitoneal disease not amenable to R0 resection, as determined by consensus in multidisciplinary meetings.
Systemic chemotherapy
Decisions regarding the chemotherapy regimens were made on an individual patient basis by medical oncologists. In the first year of this study period, treatment with 5-fluorouracil and folic acid or irinotecan was the standard palliative treatment for metastatic colorectal cancer in Japan.
3
From 2005 on, oxaliplatin was incorporated into the standard palliative treatment regimen. Targeted therapies, such as bevacizumab and cetuximab, were gradually introduced in Japan in 2007 and have been added to the combination chemotherapies ever since.
Postoperative follow-up
Patients who underwent surgery for PC from CRC had follow-up appointments every 3 months during the first 2 years, every 6 months over the next 3 years, and yearly thereafter. A physical examination and serum CEA and/or CA19-9 measurements were performed, and systemic computed tomography (CT) scans were obtained at each visit. Follow-up dates were recorded in a prospective database.
Peritoneal carcinomatosis status
The peritoneal carcinomatosis status was estimated using the 7th Japanese Classification of Colon Cancer (JCCC) [12] . This score was based upon the distance, not including the number and size, from the primary tumor (P0, no peritoneal carcinomatosis; P1, near; P2, a middle distance and P3, far from the primary tumor).
The modified glasgow prognostic score
The GPS was estimated as described previously [13, 14] . In short, patients with both an elevated CRP level (>1.0 mg/dL) and hypoalbuminemia (<3.5 g/dL) were allocated a score of 1. However, the GPS has been modified based on evidence that hypoalbuminemia in patients without an elevated CRP level has no significant association with the cancer-specific survival. Therefore, patients with an elevated CRP level were assigned an mGPS of 1 or 2 depending on the absence or presence of hypoalbuminemia, respectively [15] [16] [17] . The mGPS was defined as follows: mGPS 0, CRP ≤ 1.0 mg/dL; mGPS 1, CRP > 1.0 mg/dL and mGPS 2, CRP > 1.0 mg/dL and serum albumin <3.5 g/dL.
Statistical analyses
The survival time was defined as from the first surgical intervention day for PC from CRC to the day of death. A univariate Cox proportional analysis was performed on each clinical and histological parameter [age, sex, primary tumor site, tumor (T) stage, lymph node (N) stage, peritoneal cancer status, tumor differentiation, treatment (surgery and/or systemic chemotherapy), the presence of extraperitoneal metastasis, postoperative adverse events, the CEA and CA19-9 levels and the mGPS], with the survival date. These variables were dichotomized (i.e., either classified as pathological or not) in the analysis, and the overall survival at 3 months was the end point. All variables with values of P < 0.10 in the univariate dichotomized Cox proportional analysis were included in a multivariate Cox proportional analysis using the all-effects function (both forward and backwards analyses). The hazard ratio (HR) with the 95 % confidence interval (95 % CI) was calculated in the univariate or multivariate analysis. A Kaplan-Meier analysis and the log-rank test were used to compare the mortality for each mGPS.
The relationships between the mGPS and other variables were analyzed using the Mantel-Haenszel (X 2 ) test for trends, as appropriate. Deaths before October 31, 2013 were included in the analysis. The analyses were performed using SPSS software program (Statistical Package for Social Sciences, version 19, SPSS, Chicago, IL, USA), with the significance level set at P < 0.05.
Results
Patient characteristics
A total of 65 patients [37 males and 28 females, with a median age of 64 years (range, 17-83 years)] with synchronous PC from CRC were referred for surgical intervention between 1992 and 2012. The patients' characteristics and clinical data are summarized in Table 1 .
The 5-year overall survival (OS) rate and the median survival time (MST) were 7.5 % and 11.9 months, respectively (data not shown). The primary tumor was located in the colon in 54 patients (86.2 %). Primary tumor lymph node involvement was present in 44 patients (67.6 %) and the lymph node status was unknown in 10 patients. Forty patients (61.5 %) had both peritoneal carcinomatosis (PC) and other metastases. CCRS was performed in 17 patients (26.2 %). Postoperative adverse events occurred in nine patients (13.8 %). However, there were no high-grade postoperative adverse events or deaths within 30 days. A peritoneal carcinomatosis status of P1 was seen in 22 patients (33.9 %). Systemic chemotherapy was administered to 50 patients (76.9 %). The primary drug used for chemotherapy was 5-Fluorouracil. Oxaliplatin, irinotecan and cetuximab or bevacizumab were supplementary medications and were administered to 25 (38.4 %), 16 (24.6 %) and 16 (24.6 %) patients, respectively.
Risk factors in patients with PC from CRC who died within 3 months of surgery
In the univariate analysis, no systemic chemotherapy and mGPS (>1) were associated with a high risk of death within 3 months postoperatively (Table 2) . A multivariate analysis determined that the mGPS was the only independent risk factor associated with the 3-month mortality rate (HR, 8.087; 95 % CI, 1.512-43.254; P = 0.00001).
The relationship between the mGPS and the survival of all patients An analysis of survival determined that an elevated mGPS was associated with reduced 1-year overall survival (P = 0.001) (Fig. 1a ). Significant differences in the survival rates were found between the patients with an mGPS of 0-1 and those with an mGPS of 2 (P = 0.0004) (Fig. 1b) . The 3-month overall survival rate was significantly worse in those with an mGPS of 2 compared with those with a score of 0-1 (40 and 92.6 %, respectively; P < 0.001).
The relationship between the mGPS and the clinicopathological characteristics
The relationships between the mGPS and clinicopathological characteristics in patients with synchronous PC from CRC are shown in Table 3 . An increase in the mGPS was associated with CCRS (P = 0.038), systemic chemotherapy (P = 0.028) and the CEA level (P = 0.04). There were no significant associations between the mGPS and age (>63), sex, the primary tumor location, T stage, N stage, peritoneal cancer status, histology, postoperative adverse events, the extent of metastatic disease or the CA19-9 level.
Discussion
The goal of this study was to identify the risk factors associated with the postsurgical 3-month mortality rate in patients with synchronous PC from CRC by examining the clinicopathological -characteristics. The data showed that the mGPS is an important and independent risk factor for the 3-month mortality rate in patients who underwent surgical intervention with systemic chemotherapy for synchronous PC from CRC.
The MST for all patients with synchronous PC from CRC in this study was 11.9 months, which is similar to the MST of patients with synchronous PC from CRC found in other reports [1, 10, 18] . A number of papers have described the risk factors associated with overall survival rate in patients with PC from CRC treated by CCRS and intraperitoneal chemotherapy, which can include CCRS, metachronous PC from CRC, a limited extent of PC, age <65 years, the use of systemic chemotherapy, lymph node involvement, the presence of liver metastasis and poor histological differentiation [19] [20] [21] . However, there have been 2 from top to bottom) and the overall survival in patients with synchronous peritoneal carcinomatosis no reports of the risk factors associated with the 3-month mortality rate. In our univariate analysis focused on the 3-month mortality, a lack of systemic chemotherapy and the mGPS (>1) were identified as risk factors (Table 2 ). According to the multivariate analysis, the mGPS was the only independent risk factor (Table 2) . Interestingly, all postoperative factors faded, and only preoperative factors remained as risk factors in the multivariate analysis. In addition, the mGPS was associated with CCRS and systemic chemotherapy; all patients with an mGPS of 2 were not treated with CCRS, and only 50 % of the patients were treated with systemic chemotherapy. This may indicate that asymptomatic patients with an mGPS of 2 should not undergo surgical intervention because of the increased risk of early mortality.
The mGPS has been shown to predict cancer survival independent of the tumor site [22, 23] . Powell et al. [24, 25] investigated 411 patients with all types of colorectal cancer and reported that the mGPS was an independent risk factor related to cancer-specific survival. In the current study, although the number of patients was small, the mGPS was the only independent risk factor associated with the 3-month mortality rate. There was no significant correlation found between the 3-month mortality rate and any other clinical or histological findings, such as age, gender, and tumor location.
There are other prognostic scoring systems for CCRS and HIPEC treatment, such as the prognostic score (PS), peritoneal surface disease severity (PSDS) staging, and colorectal peritoneal (CORP) score [26] [27] [28] . The PS is calculated by multiplying every coefficient by its corresponding factor, such as the location of the primary tumor, primary tumor histopathology and peritoneal carcinomatosis index (PCI) [1] . The PSDS score is estimated based on the three prognostic factors: clinical symptoms, primary tumor histopathology and the PCI [27] . The CORP score consists of the primary tumor histopathology, serum hemoglobin levels, white cell count and the levels of four serum tumor markers (CEA, CA125, CA19-9 and CA15-3), and their changes in the preoperative period [28] . However, the current study focused only on the 3-month mortality rate in patients with synchronous PC from CRC. According to the data presented here, the mGPS can also be applied to determine the preoperative strategy (CCRS and HIPEC treatment), especially with a view to reducing early mortality.
The major limitations of this study include the fact that it was a nonrandomized study; we also did not analyze IP treatment or the peritoneal carcinomatosis index (PCI) [29, 30] . The study was not randomized because it would have been unethical to purposefully choose no surgical intervention as a treatment option, and the treatment strategy was to perform a degree of surgical intervention considered to have the potential to improve the prognosis or the symptoms of patients with PC from CRC. IP therapy was also not analyzed in this study, because until recently, treatment by IP was not standardized and was performed in only a few institutions. The PCI was not analyzed in this study because the peritoneal carcinomatosis status was based upon the distance from the primary tumor according to the JCCC guidelines; P1, P2, P3 are equivalent to a PCI of 1-9, 4-18 and 7-39, respectively. It is difficult to perfectly compare the Japanese score with the PCI, but CCRS is always performed in the cases with a P1 status.
Conclusion
In conclusion, this study determined that the mGPS is an important and independent risk factor associated with the 3-month mortality rate in patients who underwent surgical intervention with systemic chemotherapy for synchronous PC from CRC. Therefore, the mGPS could assist surgeons in preoperatively deciding on the most appropriate treatment strategy for patients with synchronous PC from CRC.
